Ximelagatran Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Ximelagatran (XII), a prodrug of a direct thrombin
inhibitor, melagatrin, was approved in the European Union
in December, 2003, for the prevention of venous
thromboembolic events in patients undergoing major
elective orthopedic surgery, that is, hip or knee replacement. The FDA, however, did not approve the drug in the
US based on the recommendation of the advisory panel.
Verwenden
Antithrombotic agent.
Ximelagatran Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
